Evidence map›Paper›PMID 37822942›Full record

ArticleFrontiers in immunology2023

MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth.

Brooke King, Bradley A Krisanits, Qi J Guo, Bobbie Blake, Lourdes M Nogueira, Gurbani Jolly, Arabia Satterwhite, David P Turner, Stanley Hoffman, Ashley Evans-Knowell and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. MicroRNAs and Cancer Racial Disparities.Wiley interdisciplinary reviews. RNA
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Brooke KingDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Bradley A KrisanitsDepartment of Surgery, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.
Qi J GuoDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Bobbie BlakeDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Lourdes M NogueiraDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Gurbani JollySchool of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Arabia SatterwhiteDepartment of Biological and Physical Sciences, South Carolina State University, Orangeburg, SC, United States.
David P TurnerDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Stanley HoffmanDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Ashley Evans-KnowellDepartment of Biological and Physical Sciences, South Carolina State University, Orangeburg, SC, United States.
Victoria J FindlayDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States.
Medical University of South Carolina · USVirginia Commonwealth University · USSouth Carolina State University · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
South Carolina Cancer Disparities Research Center (SC CADRE)U54CA210962 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CARROLL, STEVEN L. · 2017 to 2023
$6.7M
Lifestyle associated reactive metabolites and their negative impact on breast cancer riskR01CA245143 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FINDLAY, VICTORIA JANE, TURNER, DAVID PAUL · 2020 to 2024
$2.1M
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor StromaR01CA259415 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI David Paul Turner · 2023 to 2026
$1.7M
SC Cancer Disparties Research Center (1 of 2)P20CA157066 · NCI · SOUTH CAROLINA STATE UNIVERSITY · PI SALLEY, JUDITH · 2011 to 2014
$403k
NCI NIH HHS P20 CA157066NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA245143NCI NIH HHS R01 CA259415NCI NIH HHS U54 CA210962
6 · The paper itself

Abstract

Introduction: In the US, despite the recent decline in breast cancer deaths, a persistent mortality disparity exists between black and white women with breast cancer, with black women having a 41% higher death rate. Several studies are now reporting that racial disparities can exist independent of socioeconomic and standard of care issues, suggesting that biological factors may be involved. Caveolin-1 (Cav1) loss in the tumor stromal compartment is a novel clinical biomarker for predicting poor outcome in breast cancer including triple negative subtype, however the mechanism of Cav1 loss is unknown. We previously identified miR-510-5p as a novel oncomir and propose here that the high levels observed in patients is a novel mechanism leading to stromal Cav1 loss and worse outcomes. Methods: Cav1 was identified as a direct target of miR-510-5p through luciferase, western blot and qPCR assays. Stromal cross talk between epithelial cells and fibroblasts was assessed Results: We found that Cav1 is a direct target of miR-510-5p and that expression in fibroblasts results in an 'activated' phenotype. We propose that this could be important in the context of cancer disparities as we also observed increased levels of circulating miR-510-5p and reduced levels of stromal Cav1 in black women compared to white women with breast cancer. Finally, we observed a significant increase in tumor growth when tumor cells were co-injected with miR-510-5p expressing cancer associated fibroblasts Conclusion: We propose that miR-510-5p mediated negative regulation of Cav1 in fibroblasts is a novel mechanism of aggressive tumor growth and may be a driver of breast cancer disparity.

Indexed as

Breast NeoplasmsCaveolin 1MicroRNAsCell Line, TumorFemaleFibroblastsHumansCAV1 protein, humanCaveolin 1MicroRNAsMIRN510 microRNA, humanbreast cancerCaveolin-1disparitiesmicroRNAstroma

Identifiers

PMID37822942
PMCPMC10564112
OpenAlexW4387058497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.